Clinical Trials
Evaluating potential of investigational medicines
- ONC201: Phase 3 ACTION Study
The ACTION study is enrolling newly diagnosed diffuse glioma patients whose tumor harbors the H3 K27M-mutation. The study is a world wide randomized, double-blind, placebo-controlled Phase 3 clinical trial. Treatment with ONC201 begins shortly after completion of radiation therapy. The primary endpoint of the study is overall survival (OS). The study will take place at 95 sites in Canada, Brazil, Argentina, Europe, and Asia Pacific, including Japan.
If you would like more information about the ACTION study, please contact us at [email protected]
- ONC206
The first-in-human clinical trial for adults with recurrent primary CNS tumors is ongoing at the National Institute of Health and in pediatric CNS tumors with the Pacific Pediatric Neuro-Oncology Consortium.